Replimune Group, Inc. — Form 10-Q summary
Reporting period: Three months ended June 30, 2022, the company’s fiscal first quarter. The company is a clinical-stage biotechnology business developing oncolytic immunotherapies. It had no approved products and generated no product revenue.
Financial results and position
| Metric | Q1 FY2023 | Prior-year quarter |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $29.5 million | $18.6 million |
| Selling, general and administrative expense | $11.4 million | $8.8 million |
| Total operating expenses / operating loss | $40.9 million | $27.4 million |
| Net loss | $42.3 million | $27.3 million |
| Net loss per share, basic and diluted | $0.78 | $0.53 |
| Net cash used in operating activities | $33.5 million | $18.3 million |
Amounts are in U.S. dollars. No meaningful revenue margin was reported because the company had no product sales. Other income and expense included $2.0 million of net other expense, primarily foreign-exchange losses, partly offset by investment income.
- Liquidity: At June 30, cash and cash equivalents were $112.2 million and short-term investments were $282.8 million, totaling $395.1 million. Cash, cash equivalents and restricted cash at period end were $113.9 million.
- Cash flow and financing: Investing activities provided $5.3 million; financing activities provided $32.5 million, including $31.0 million net proceeds from ATM share sales. Cash, cash equivalents and restricted cash increased $6.3 million during the quarter.
- Debt and leases: The balance sheet reports no conventional borrowings. Finance-lease liabilities totaled $26.9 million and operating-lease liabilities $5.6 million; total liabilities were $49.2 million.
- Equity: Accumulated deficit was $353.5 million. Shares outstanding increased from 47.3 million at March 31 to 49.3 million at June 30, primarily reflecting ATM sales, option exercises and equity awards.
Changes versus the prior-year quarter
- Net loss widened by $14.9 million. R&D expense rose $10.9 million, reflecting expanded clinical activity, manufacturing technology transfer and process development, and higher personnel costs. SG&A increased $2.6 million, including added hiring and pre-commercial planning.
- Operating cash use increased by $15.1 million, broadly consistent with the higher net loss and increased development spending.
- Net other income of $0.1 million shifted to net other expense of $1.4 million, principally because of unfavorable GBP/USD movements on intercompany and other non-functional-currency transactions.
Outlook, development programs and risks
- Runway: Management said existing cash and short-term investments should fund planned operating expenses and capital needs into the second half of calendar 2024, excluding any confirmatory trial required by regulators. The filing also says cash and investments are expected to cover at least 12 months from issuance. These estimates depend on assumptions and may prove inaccurate; management expects additional financing will ultimately be needed.
- Clinical milestones: CERPASS, a registration-directed Phase 2 trial of RP1 plus cemiplimab versus cemiplimab alone in cutaneous squamous cell carcinoma, had reached its target enrollment of 180 evaluable patients; topline primary-analysis data were expected in the first half of 2023. The company expected an IGNYTE RP1 melanoma-cohort data snapshot in late 2022, and initial expanded-cohort data for RP2 and RP3 toward year-end 2022. A neoadjuvant RP1 study was expected to begin in the first half of 2023; RP2/RP3 Phase 2 signal-finding work was planned to start in Q1 2023.
- Regeneron cost-sharing item: Regeneron said in July that reimbursement under CERPASS’s initial budget had been completed. The companies were discussing cost sharing under a superseding budget. A $1.4 million amount due to Replimune for the quarter was not recorded in the balance sheet or as an R&D expense offset; the filing does not establish that the amount will be collected.
- Capital raising and dilution: A new ATM agreement allows sales of up to $100 million of common stock. Further sales could dilute shareholders. The quarter’s ATM sales generated $31.0 million net proceeds.
- Key risks: The company expects continuing losses and increasing R&D spending; candidates may fail clinical or regulatory testing; enrollment, COVID-19, manufacturing transfer, supply constraints, and reliance on collaborators could delay development. The company also cites competition, foreign-exchange exposure, and the possibility that additional capital may not be available on acceptable terms.
- Controls and contingencies: Management concluded disclosure controls were effective at a reasonable-assurance level, with no material change in internal control over financial reporting during the quarter. The company reported no material legal proceedings.
Important facts for investors to verify
- Progress, timing and results of CERPASS, IGNYTE, and the RP2/RP3 trials, including whether regulatory authorities consider the data sufficient for a filing.
- Whether Regeneron acknowledges and pays the disputed $1.4 million cost-sharing amount, and how future CERPASS costs are allocated.
- Actual cash burn, trial and manufacturing costs, and whether the stated runway remains achievable—especially if confirmatory trials are required.
- Any additional ATM share issuance and its effect on outstanding shares and per-share value.
- Whether in-house manufacturing comparability, qualification and supply plans proceed without disrupting clinical programs.